Journal Article

Structural and functional comparability study of anti-CD20 monoclonal antibody with reference product

Pokalwar, Santosh, Singh, Sanjay Kumar, Gupta, Shivika, Bose, Sandip, Ranbhor, Ranjit Sudhakar, Almal, Suhani

2018

Overview

Cell surface protein, CD20, is extensively expressed on the surface of B cells. Antibodies targeting CD20 protein are being used to treat B-cell malignancies and B-cell mediated autoimmune diseases. Considering the cost of therapy with innovator monoclonal antibodies for these diseases, development of biosimilar products for the treatment of such diseases provides affordable solution to rising healthcare costs. Reference products of rituximab (six batches) were procured and stored as per manufacturer's instructions. Cell lines used in bioassay were procured from American Type Culture Collection and all other reagents used for analysis were of analytical grade. Primary structure was studied by intact mass analysis, peptide fingerprinting, peptide mass fingerprinting and sequence coverage analysis. Higher order structure was studied by circular dichroism, ultraviolet-visible spectroscopy, fluorescence spectroscopy, and disulfide bridge analysis. Different isoforms of reference product and SB-02 were identified using capillary isoelectric focusing and capillary zone electrophoresis. Glycosylation was studied by N-glycan mapping using LC-ESI-MS, point of glycosylation, released glycan analysis using ultra performance liquid chromatography (UPLC). Product related impurities such as oligomer content analysis and oxidized impurities were studied using size exclusion chromatography and reverse phase high performance liquid chromatography, respectively. Here, we report physicochemical and biological characterizations of Sun Pharma's proposed biosimilar (SB-02) to rituximab, a monoclonal anti-CD20 antibody approved for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. SB-02 and rituximab exhibited indistinguishable primary as well as higher-order structure upon analyzing with the array of analytical and extended characterization methods according to statistical methods. The molecule also displayed comparability to reference product in post-translational modifications and charge heterogeneity. In functional bioassays, SB-02 demonstrated comparable potency with respect to reference product. Our results indicate highly similar quality profile between SB-02 and rituximab.

• Publisher: Dove Medical Press Limited,Taylor & Francis Ltd,Dove Press,Dove Medical Press
• Subject: ADCC / Amino acids / Antibodies / Arthritis / Autoimmune diseases / B cells / Backup software / Biological products / Biopharmaceuticals / Biosimilar / Biosimilarity / CD20 / CDC / Chromatography / Chronic lymphocytic leukemia / Electrophoresis / Enzymes / FDA approval / Fluorescence / Fluorescence spectroscopy / Health care costs / High performance liquid chromatography / Immunotherapy / Leukemia / Liquid chromatography / Lymphocytic leukemia / Lymphoma / Lymphomas / Mass spectrometry / Medical economics / Medical innovations / Molecular weight / Monoclonal antibodies / monoclonal antibody / Original Research / Patient Protection & Affordable Care Act 2010-US / Peptides / Pharmaceuticals / Product introduction / Proteins / Regulatory agencies / rituximab / Scientific imaging / Spectroscopy / Statistical methods / Targeted cancer therapy / Tumors / Ultraviolet-visible spectroscopy